Dow Up0.08% Nasdaq Down0.30%

Amarantus Bioscience Holdings, Inc (AMBS)

-Other OTC
0.09 Down 0.00(4.58%) Sep 19, 3:58PM EDT
ProfileGet Profile for:
Amarantus Bioscience Holdings, Inc
953 Indiana Street
San Francisco, CA 94107
United States - Map
Phone: 408-737-2734
Fax: 408-852-4427

Index Membership:N/A
Full Time Employees:3

Business Summary 

Amarantus BioScience Holdings, Inc., a development stage biotechnology company, focuses on the discovery and development of drug and diagnostic product candidates to treat human diseases in the United States. The company’s principal products in development include the lymphocyte proliferation test, a diagnostic blood test for Alzheimer’s disease; Eltoprazine, a small molecule drug candidate, which is used for the treatment of Parkinson’s disease medication Levadopa-Induced Dyskinesia and Adult Attention Deficit Hyperactivity Disorders that is in Phase II clinical trials; and Mesencephalic Astrocyte-derived Neurotrophic factor, a therapeutic protein for use in Parkinson’s disease and other apoptosis-related disorders treatment. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Amarantus Bioscience Holdings, Inc

Key Executives 
Mr. Gerald E. Commissiong , 32
Chief Exec. Officer, Pres and Director
Mr. Marc E. Faerber , 59
Principal Accounting Officer, VP of Financial Operations, Treasurer, Sec. and Corp. Controller
Dr. John W. Commissiong Ph.D., 70
Chief Scientific Officer and Director
Mr. Robert Lewis Harris , 70
Compliance Officer, Independent Director, Chairman of Governance & Nominating Committee, Member of Compensation Committee and Member of Audit Committee
Mr. Robert E. Farrell J.D., Esq., 64
Chief Financial Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders